Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Cubist Pharmaceuticals |
---|---|
Information provided by: | Cubist Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00295178 |
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters:
Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.
Condition | Intervention | Phase |
---|---|---|
Cellulitis |
Drug: Daptomycin Drug: Vancomycin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment |
Official Title: | A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas |
Estimated Enrollment: | 80 |
Study Start Date: | March 2006 |
Estimated Study Completion Date: | August 2006 |
same as above
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Primary diagnosis of cellulitis/ erysipelas
Exclusion Criteria:
United States, Georgia | |
Joseph Still Research Foundation | |
Augusta, Georgia, United States, 30909 |
Principal Investigator: | Bruce Friedman, MD | Joseph M. Still Research Foundation, Inc. |
Study ID Numbers: | DAP-4CELL-05-02 |
Study First Received: | February 21, 2006 |
Last Updated: | December 14, 2006 |
ClinicalTrials.gov Identifier: | NCT00295178 |
Health Authority: | United States: Institutional Review Board |
Bacterial Infections Skin Diseases Inflammation Daptomycin Cellulitis Skin Diseases, Infectious Gram-Positive Bacterial Infections |
Streptococcal Infections Skin Diseases, Bacterial Connective Tissue Diseases Erysipelas Suppuration Vancomycin |
Anti-Infective Agents Anti-Bacterial Agents Pathologic Processes |
Therapeutic Uses Infection Pharmacologic Actions |